Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or.
Proyecto:
Ministerio de Ciencia e Innovación PS09/01370
,
Ministerio de Economía y Competitividad PI12/01761
,
Ministerio de Economía y Competitividad CD13/00340
,
Ministerio de Economía y Competitividad JR14/00016
,
Ministerio de Economía y Competitividad RD12/0036/0048
,
Ministerio de Economía y Competitividad RD12/0036/0058